Back to Publications
August, 2021

MORNINGSKY Trial

BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial

BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial, a global multicenter study evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.
 

Learn more at https://www.covid19morningsky.com/PT

Other Publication


BlueClinical is a proud gold sponsor of the 2nd Bioequivalence Workshop

We are happy to announce that BlueClinical is a proud gold sponsor of the 2nd Bioequivalence Workshop by Medicines for Europe, which is scheduled to take place on 26 April 2023 in Brussels, Belgium.

Privacy and Data Protection Policy

Privacy and Data Protection Policy Update